Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca plc    AZN   GB0009895292

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

AstraZeneca : Top AstraZeneca shareholder Woodford adds to stake, bullish on outlook

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/17/2017 | 10:43am CET
A sign is seen at an AstraZeneca site in Macclesfield

Top AstraZeneca (>> AstraZeneca plc) shareholder Woodford Investment Management said on Wednesday it had added to its stake in the pharmaceutical firm and was confident in its growth outlook.

Top AstraZeneca (>> AstraZeneca plc) shareholder Woodford Investment Management said on Wednesday it had added to its stake in the pharmaceutical firm and was confident in its growth outlook.

Woodford, in an update on its website, said shares in AstraZeneca had been unfairly hit since analysts raised concern about the prospects for its key cancer drug trial, Mystic, after rival Bristol-Myers Squibb (>> Bristol-Myers Squibb Co) scaled back its plans in a similar area.

"Whilst this is understandable to an extent, we think the reaction is wrong. Indeed, Bristol-Myers Squibb’s problems in this setting may well turn out to be positive for AstraZeneca," Mitchell Fraser-Jones said in a note to investors.

Fraser-Jones said Woodford believed AstraZeneca was on a path to return to growth regardless of the outcome of Mystic, although it was nevertheless optimistic that Mystic would be successful when results are released later this year.

(Adds dropped word "trial" in second paragraph.)

(Reporting by Simon Jessop; Editing by Susan Fenton)

Stocks treated in this article : Bristol-Myers Squibb Co, AstraZeneca plc
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ASTRAZENECA PLC
02/23 ASTRAZENECA : Phase III breast cancer trial met primary endpoint
02/21 ASTRAZENECA : Drugs giant in new rights deal
02/21 ASTRAZENECA : *berenberg cuts astrazeneca price target to 5450 pence - 'buy'
02/21 ASTRAZENECA : in $320m cancer treatment deal
02/21 ASTRAZENECA : County surveyor looks to resolve ditch issues
02/20 ASTRAZENECA : selling U.S., Canadian rights to cancer drug
02/20 British FTSE 100 decreases 0.34 pct on Thursday
02/20 LONDON MARKET PRE-OPEN : Stocks Seen Up; AstraZeneca Signs Deal In US
02/20DJASTRAZENECA : licenses Cancer Drug Zoladex to TerSera for the US, Canada
02/20 TOP NEWS : AstraZeneca Signs Deal For Zoladex Rights In North America
More news
Sector news : Pharmaceuticals - NEC
12:59a Exclusive - Trump says Republican border tax could boost U.S. jobs
02/23DJPFIZER : Files 8K - Changes Executive Management
02/23DJGlaxoSmithKline Reports Positive Study Results for Asthma Drug
02/23DJPURETECH HEALTH : Appoints Atul Pande as Chief Medical Officer
02/23DJBAYER : Financing Plan Will Raise Equity First Then Bonds -- WSJ
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
02/23 Is Pfizer's Research Pipeline Truly Undervalued?
02/23 Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q4 2016 Update
02/22 Should Merck, BMS Fear Roche's Drug Becoming The I-O King?
02/22 Chi-Med Looks Outside Its Comfort Zone
02/22 Tersera Gives Zoladex A Life After Death
Advertisement
Financials ($)
Sales 2017 21 588 M
EBIT 2017 5 790 M
Net income 2017 2 747 M
Debt 2017 11 853 M
Yield 2017 4,79%
P/E ratio 2017 25,73
P/E ratio 2018 20,98
EV / Sales 2017 3,91x
EV / Sales 2018 3,80x
Capitalization 72 464 M
More Financials
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca plc Technical Analysis Chart | AZN | GB0009895292 | 4-Traders
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 33
Average target price 62,7 $
Spread / Average Target 8,6%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Dunoyer Chief Financial Officer & Executive Director
Sean Bohen Chief Medical Officer & Executive Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC3.55%72 464
JOHNSON & JOHNSON3.74%331 089
ROCHE HOLDING LTD.5.98%209 906
PFIZER INC.3.42%206 688
NOVARTIS AG3.51%201 806
MERCK & CO., INC.10.91%181 558
More Results